Gastroenterology

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

Source link




Related posts

Diagnosis, risk stratification, and management of ampullary dysplasia by DNA flow cytometric analysis of paraffin-embedded tissue

Newsemia

A set of molecular markers predicts chemosensitivity to Mitomycin-C following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis

Newsemia

Anti-TNFs linked to new onset psoriasis in pediatric IBD

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy